Heidi Nyman

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy

Heidi Nyman, Magdalena Adde, Marja‐Liisa Karjalainen‐Lindsberg et al. · Blood · 2007 · 280 citations · Full text

Medicine, Oncology, Pathology +16

A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone

Minna Taskinen, Marja‐Liisa Karjalainen‐Lindsberg, Heidi Nyman et al. · Clinical Cancer Research · 2007 · 210 citations

Medicine, Immunology, Oncology +17

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP

Heidi Nyman, Mats Jerkeman, Marja‐Liisa Karjalainen‐Lindsberg et al. · Modern Pathology · 2009 · 106 citations · Full text

Medicine, Hematology, Oncology +14

Differential gene expression in non‐malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP

Antti Harjunpää, Minna Taskinen, Matti Nykter et al. · British Journal of Haematology · 2006 · 39 citations · Full text

Medicine, Immunology, Oncology +17

Bcl‐2 but not FOXP1, is an adverse risk factor in immunochemotherapy‐treated non‐germinal center diffuse large B‐cell lymphomas

Heidi Nyman, Mats Jerkeman, Marja‐Liisa Karjalainen‐Lindsberg et al. · European Journal Of Haematology · 2009 · 38 citations

Medicine, Cancer Biology, Oncology +13